Multimodal Assessment of Sarcopenia Using Shear Wave Elastography, Dual-Energy X-ray Absorptiometry, Bioelectrical Impedance Analysis, and Physical Performance Measures
The goal of this observational study is to learn whether shear wave elastography (SWE) parameters, combined with dual-energy X-ray absorptiometry (DXA), bioelectrical impedance analysis (BIA), and physical performance assessments, can help diagnose sarcopenia in older adults. The main questions it aims to answer are:
- Are SWE-derived muscle stiffness parameters associated with muscle mass, muscle strength, and physical performance?
- Can an integrated model including SWE parameters accurately identify sarcopenia compared with the DXA-based diagnosis?
Researchers will compare participants with sarcopenia to those without sarcopenia, to see if SWE parameters differ between groups and contribute to sarcopenia prediction.
Participants will:
- Undergo shear wave elastography of selected skeletal muscles
- Receive a DXA scan to measure appendicular skeletal muscle mass
- Receive a BIA measurement of body composition
- Complete muscle strength and physical performance assessments
研究概览
地位
条件
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名:Ming Hsuan Huang, MD
- 电话号码:+886 073422121
- 邮箱:min0711@vghks.gov.tw
学习地点
-
-
-
Kaohsiung City、台湾、807
- 招聘中
- Kaohsiung Veterans General Hospital
-
接触:
- Ming Hsuan Huang
- 电话号码:886-0933603324
- 邮箱:tatat6918@gmail.com
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
Participants will be recruited from the outpatient clinics or inpatient ward of Kaohsiung Veterans General Hospita, Taiwan.
描述
Inclusion Criteria:
- Adults aged 65 years and older
- Able to walk independently, with or without an assistive device
- Able to understand study procedures and provide written informed consent
- Able to perform related exam
Exclusion Criteria:
- Implanted electronic medical devices (e.g., cardiac pacemaker or defibrillator), which contraindicate BIA measurement
- Metal implants or prostheses in the regions measured by DXA or ultrasound
- History of fracture or surgery of the lower extremities within the past 6 months
- Neuromuscular disease affecting skeletal muscle (e.g., stroke with residual limb weakness, Parkinson's disease, myopathy, or amyotrophic lateral sclerosis)
- Skin lesions, wounds, or infection at the ultrasound measurement sites
- Acute illness or hospitalization within the past 4 weeks
- Cognitive impairment or psychiatric conditions that preclude completion of study assessments
- Inability to complete muscle strength or physical performance tests
学习计划
研究是如何设计的?
设计细节
- 观测模型:COHORT
- 时间观点:PROSPECTIVE
队列和干预
团体/队列 |
|---|
|
Sarcopenia
Participants diagnosed with sarcopenia according to the Asian Working Group for Sarcopenia (AWGS) 2025 consensus, defined as concurrent low muscle strength and low DXA-measured appendicular skeletal muscle mass. |
|
Non-sacropenia
Participants who do not meet the AWGS 2025 criteria for sarcopenia. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Diagnostic accuracy of shear wave elastography parameters for sarcopenia
大体时间:Within 2 weeks of enrollment
|
Area under the receiver operating characteristic curve (AUC), sensitivity, and specificity of SWE parameters, alone and combined with BIA and physical performance measures, for identifying sarcopenia as defined by the AWGS 2025 consensus. |
Within 2 weeks of enrollment
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Appendicular skeletal muscle mass index measured by DXA
大体时间:Within 2 weeks of enrollment
|
Appendicular skeletal muscle mass divided by height squared (kg/m²), measured by dual-energy X-ray absorptiometry. |
Within 2 weeks of enrollment
|
|
Skeletal muscle mass index measured by BIA
大体时间:Within 2 weeks of enrollment
|
Appendicular skeletal muscle mass divided by height squared (kg/m²), measured by bioelectrical impedance analysis. |
Within 2 weeks of enrollment
|
|
Handgrip strength
大体时间:Within 2 weeks of enrollment
|
Maximum handgrip strength (kg) of the dominant hand measured with a handheld dynamometer. |
Within 2 weeks of enrollment
|
合作者和调查者
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- 26-CT7-09(260617-1)
- KSVGH115-181 (其他标识符:KaohsiungVGH)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Individual participant data will not be shared publicly due to participant privacy and confidentiality requirements under Taiwan's Personal Data Protection Act and the conditions of institutional review board approval. De-identified data may be made available from the corresponding author upon reasonable request, subject to approval by the institutional review board.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.